BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 15338554)

  • 21. Chronic myeloid leukemia with hyperdiploidy: a case report with review of literature.
    Belurkar S; Manohar C; Kurien A
    Indian J Med Sci; 2013; 67(7-8):188-92. PubMed ID: 24469564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
    Cortes J; Rousselot P; Kim DW; Ritchie E; Hamerschlak N; Coutre S; Hochhaus A; Guilhot F; Saglio G; Apperley J; Ottmann O; Shah N; Erben P; Branford S; Agarwal P; Gollerkeri A; Baccarani M
    Blood; 2007 Apr; 109(8):3207-13. PubMed ID: 17185463
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
    Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.
    Thota NK; Gundeti S; Linga VG; Coca P; Tara RP;
    Indian J Cancer; 2014; 51(1):5-9. PubMed ID: 24947087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hematopathologic and cytogenetic findings in imatinib mesylate treated chronic myelogenous leukemia patients: 2.5 years' experience.
    Cojbasić I; Macukanović-Golubović L
    Vojnosanit Pregl; 2010 Oct; 67(10):802-6. PubMed ID: 21061842
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
    Guilhot F; Apperley J; Kim DW; Bullorsky EO; Baccarani M; Roboz GJ; Amadori S; de Souza CA; Lipton JH; Hochhaus A; Heim D; Larson RA; Branford S; Muller MC; Agarwal P; Gollerkeri A; Talpaz M
    Blood; 2007 May; 109(10):4143-50. PubMed ID: 17264298
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Morphological effects of imatinib mesylate (STI571) on the bone marrow and blood of patients with Philadelphia chromosome (Ph) positive chronic myeloid leukaemia.
    McNamara C; Grigg A; Szer J; Roberts A; Campbell L; Hoyt R; Lynch K; Juneja S
    Clin Lab Haematol; 2003 Apr; 25(2):119-25. PubMed ID: 12641616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Research advance on molecular genetics of CML blast crisis].
    Zhu HQ; Zhang S; Liu XL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response.
    Hasserjian RP; Boecklin F; Parker S; Chase A; Dhar S; Zaiac M; Olavarria E; Lampert I; Henry K; Apperley JF; Goldman JM
    Am J Clin Pathol; 2002 Mar; 117(3):360-7. PubMed ID: 11888075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combining nilotinib and imatinib improves the outcome of imatinib-resistant blast phase CML.
    Zhu GR; Ji O; Ji JM; Zhang YC; Wu Y; Yu H; Jiang PJ; Shen Q
    Acta Haematol; 2012; 127(3):152-5. PubMed ID: 22286512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy.
    Bujassoum S; Rifkind J; Lipton JH
    Leuk Lymphoma; 2004 Feb; 45(2):401-3. PubMed ID: 15101732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
    Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Qiu JY; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):23-6. PubMed ID: 15946504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases.
    Higashi T; Tsukada J; Kato C; Iwashige A; Mizobe T; Machida S; Morimoto H; Ogawa R; Toda Y; Tanaka Y
    Am J Hematol; 2004 Jul; 76(3):275-8. PubMed ID: 15224366
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
    Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G;
    Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
    Cortes JE; Talpaz M; Giles F; O'Brien S; Rios MB; Shan J; Garcia-Manero G; Faderl S; Thomas DA; Wierda W; Ferrajoli A; Jeha S; Kantarjian HM
    Blood; 2003 May; 101(10):3794-800. PubMed ID: 12560227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
    Kantarjian HM; Talpaz M; O'Brien S; Smith TL; Giles FJ; Faderl S; Thomas DA; Garcia-Manero G; Issa JP; Andreeff M; Kornblau SM; Koller C; Beran M; Keating M; Rios MB; Shan J; Resta D; Capdeville R; Hayes K; Albitar M; Freireich EJ; Cortes JE
    Clin Cancer Res; 2002 Jul; 8(7):2177-87. PubMed ID: 12114418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate.
    Zonder JA; Schiffer CA
    Curr Hematol Malig Rep; 2006 Sep; 1(3):141-51. PubMed ID: 20425345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted chronic myeloid leukemia therapy: Seeking a cure.
    Fausel C
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dasatinib treatment for imatinib resistant or intolerant patients with chronic myeloid leukaemia.
    Li J; Xu G; Yu S; He L; Guo L
    J Int Med Res; 2011; 39(2):337-47. PubMed ID: 21672337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Promyelocytic blast crisis of chronic myeloid leukemia during imatinib treatment.
    Chung HJ; Chi HS; Cho YU; Park CJ; Seo EJ; Kim KH; Lee JH
    Ann Clin Lab Sci; 2008; 38(3):283-6. PubMed ID: 18715859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.